| Document |
Document Title |
|
WO/2022/226100A1 |
The present disclosure provides, inter alia, antibodies with covalently attached biocompatible polymeric moieties, that are useful in treating various diseases such as cancer and autoimmune disorders.
|
|
WO/2022/225007A1 |
The present invention addresses the problem of providing an actinium-225-labeled anti-MUC5AC humanized antibody exhibiting excellent specificity to mucin subtype 5AC (MUC5AC), excellent clustering in tumors, and reduced kidney toxicity. ...
|
|
WO/2022/225960A1 |
The invention provides a method for applying diarylhydantoin compounds, including flutamide, bicalutamide, enzalutamide, apalutamide, and proxalutamide, to treat sepsis and conditions that mimic sepsis.
|
|
WO/2022/224644A1 |
Provided is a novel material that can inhibit TARC related to pathogenesis of various inflammatory diseases, and that is effective in therapy and the like for, for example, atopic dermatitis. This material is a kumis-derived exosome–co...
|
|
WO/2022/224962A1 |
The present invention addresses the problem of providing a pharmaceutical composition / drug combination which makes it possible to prevent and/or treat dyslipidemia such as hypercholesterolemia and hypertriglyceridemia, or cardiovascula...
|
|
WO/2022/224776A1 |
A lipid decrease promoter containing IPQ and/or a salt thereof as an active ingredient.
|
|
WO/2022/218237A1 |
A granule capable of nourishing Yin, nourishing internal organs and cooling blood is prepared from a component A and a component B. The active pharmaceutical ingredients of the component A comprise Fresh Rehmannia Root, Prepared Rehmanni...
|
|
WO/2022/220179A1 |
[Problem] To provide a novel preparation for periodontal tissues, which enables a treatment to be performed by a simple operation, can achieve high periodontal tissue regeneration performance, and can achieve a high regeneration effect f...
|
|
WO/2022/219172A1 |
The present invention relates to inhibitors of hexokinase-dependent glucose carrier-mediated glucose uptake (Warbicins) that can be used to inhibit proliferation of cancer cells and other cells with an overactive glucose uptake and catab...
|
|
WO/2022/221522A1 |
Disclosure herein are an implantable cell containing device, its subcomponent scaffold, methods of making the same and their methods of use. The implantable cell containing device includes a scaffold and a cell -containing hydrogel encap...
|
|
WO/2022/220147A1 |
The present invention provides a muscle atrophy inhibition composition. Specifically, the present invention provides a muscle atrophy inhibitor that includes a CXCL10 expression inhibitor as an active ingredient.
|
|
WO/2022/220227A1 |
Provided is a tetrahydropyridopyrimidine compound which has Axl inhibitory activity and selectively inhibits Axl over Mer.
|
|
WO/2022/220265A1 |
Provided is a novel use of S-1-propenylcysteine, a salt thereof or a composition containing the same. A Sirtuin or Klotho activator or expression enhancer that comprises S-1-propenylcysteine or a salt thereof as an active ingredient.
|
|
WO/2022/215568A1 |
The purpose of the present invention is to provide a novel technique for directly promoting muscle synthesis without physical activity and preventing muscle atrophy. Provided is: a muscle synthesis promoting agent or muscle atrophy pre...
|
|
WO/2022/215441A1 |
Provided is a novel active ingredient derived from carob and a usage therefor. The present invention is a compound represented by formula (I) or a salt thereof, or a solvate of the compound or the salt.
|
|
WO/2022/214025A1 |
Disclosed in the present invention are a pegylated lipid, a preparation method therefor, a liposome containing the pegylated lipid, a pharmaceutical composition containing the liposome, a preparation thereof, and the use thereof, belongi...
|
|
WO/2022/215619A1 |
The present invention addresses the problem of providing a composition capable of effectively promoting GLP-1 secretion. This problem can be solved by providing a composition for promoting GLP-1 secretion that comprises, as active ingred...
|
|
WO/2022/215754A1 |
Provided is a bicyclic pyridine derivative. A compound represented by formula I [wherein: X represents an oxygen atom, a sulfur atom, NR or CR'R"; n is 0 or 1; R1, R2a, R2b, R2c, R2d, R, R' and R" independently represent a hydrogen atom,...
|
|
WO/2022/215622A1 |
The present invention pertains to: a pyrrole-imidazole polyamide compound that has a specific structure, or a salt thereof; a membrane protein gene expression inhibitor that includes the compound or a salt thereof; and a cancer metastasi...
|
|
WO/2022/215566A1 |
[Problem] The present invention addresses the problem of discovering a molecule that is selectively expressed in mast cells and providing a prophylactic or therapeutic agent for allergic diseases. [Solution] This prophylactic or therapeu...
|
|
WO/2022/216965A1 |
Provided are methods for treating a solid cancer in a subject by administering an effective amount of a radioconjugated CCR8-targeting agent to deplete tumor-associated CCR8-positive Treg cells, alone or in combination with one or more a...
|
|
WO/2022/215679A1 |
The purpose of the present invention is to provide an antibody against pancreatic cancer stem cells. This antibody against pancreatic cancer stem cells includes a heavy chain variable region including heavy chain CDRs described as HCDR1-...
|
|
WO/2022/213895A1 |
The present invention provides a novel cationic lipid having a structure as shown in general formula (1) and particularly relates to a nitrogen-branched cationic lipid, and also relates to a liposome containing the cationic lipid, and a ...
|
|
WO/2022/215658A1 |
The present invention addresses the problem of providing a compound that binds to PGRMC1 and inhibits the function of PGRMC1. The present invention provides a PGRMC1 function inhibitor comprising glycyrrhizin, a glycyrrhizin derivative, ...
|
|
WO/2022/213664A1 |
The present invention belongs to the field of biomedicine, and mainly relates to an application of HDAC2 and DNMT1 inhibitors in the treatment of non-alcoholic steatohepatitis. The provided application of HDAC2 and DNMT1 inhibitors in th...
|
|
WO/2022/217059A1 |
Compounds comprising an isobaric region, an enrichment handle, and a thiol- reactive group are generally described. Methods of using the same (e.g., performing multiplexed quantitative analysis of the reactivity of one or more cysteine r...
|
|
WO/2022/213704A1 |
Provided are a high-migration mesenchymal stem cell, and a preparation method therefor and an application thereof. The preparation method comprises: inoculating and suspending mesenchymal stem cells in a mesenchymal stem cell culture sol...
|
|
WO/2022/214026A1 |
Disclosed in the present invention are a pegylated lipid and a preparation method therefor, a liposome comprising the pegylated lipid, and a pharmaceutical composition comprising the liposome and a preparation and use thereof, relating t...
|
|
WO/2022/217066A1 |
New methods, compositions and kits that comprise perampanel are provided for treating a subject having a SYNGAP1 neurodevelopmental disorder, including to treat conditions of sleep disorder, behavior problems and/or myoclonic or reflex s...
|
|
WO/2022/214455A1 |
The invention relates to compositions for the improvement of sport performance comprising Leucine, Isoleucine, Valine, Arginine and Glutamine, compounds of formula (I) and at least one acceptable carrier.
|
|
WO/2022/217116A1 |
This disclosure provides antibodies and antigen-binding fragments that can be administered to a subject that has been bitten by a venomous snake. Antibodies and antigen-binding fragments herein can be capable of treating or curing the su...
|
|
WO/2022/213502A1 |
Provided are an application of thyroxine in preparation of a drug for treating delayed embryonic development or incomplete embryonic development, an application of the thyroxine in preparation of a reagent for promoting growth, metabolis...
|
|
WO/2022/216101A1 |
The present invention relates to a novel indolizine derivative compound, and a composition for preventing or treating fibrosis or inflammatory diseases, comprising same as an active ingredient. An indolizine derivative of the present inv...
|
|
WO/2022/210829A1 |
Provided is a tablet: containing 55-95 mass% abiraterone acetate, as an active ingredient, to the total mass of the tablet, a solubilizing agent, and an aluminate metasilicate; being a small tablet having the content of abiraterone aceta...
|
|
WO/2022/208170A1 |
Use of a splicing modulator for a treatment slowing progression of Huntington's disease.
|
|
WO/2022/208976A1 |
The present invention addresses the problem of investigating whether serpinB2 can exhibit cell-activating activity as a result of skin external administration thereof, and providing a cell activator whereby stable quality can be ensured ...
|
|
WO/2022/211129A1 |
As an antisense oligonucleotide derivative that can suppress ATN1 gene expression and treat dentatorubral-pallidoluysian atrophy, the present invention provides a single-stranded oligonucleotide or a pharmaceutically acceptable salt ther...
|
|
WO/2022/210296A1 |
Provided are a new oxytocin signal enhancer and a new oxytocin-induced keratinocyte proliferation-promoting agent. The present invention provides an oxytocin signal enhancer and an oxytocin-induced keratinocyte proliferation-promoting ...
|
|
WO/2022/212489A1 |
Described herein are MK2 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of autoimmune disorders, chronic inflammatory disorders, acute inflammato...
|
|
WO/2022/210232A1 |
The composition contains barley grass and is used to promote IgA secretion into saliva, to maintain or improve oral cavity immune function or mucous membrane immune function, and to prevent or mitigate upper respiratory tract infections.
|
|
WO/2022/210524A1 |
The present invention addresses the problem of providing a nitrogen-containing compound effective for inhibiting cancer stem cell proliferation. This problem is solved by a nitrogen-containing compound represented by general formula (I...
|
|
WO/2022/209593A1 |
The present invention provides a cytokine production suppressing composition containing D-allose as an active component. The present invention further provides a method of treating or preventing diseases associated with cytokine overprod...
|
|
WO/2022/210802A1 |
The purpose of the present invention is to provide a novel agent for the prevention or treatment of muscular atrophy. The present invention provides an agent for the prevention or treatment of muscular atrophy, wherein the agent contains...
|
|
WO/2022/207846A1 |
This invention relates to antibodies that bind to and inhibit the activity of glial cell-derived neurotrophic factor family receptor alpha like (GFRAL) protein. The invention also relates to the GDF15-GFRAL signalling pathway as a therap...
|
|
WO/2022/211481A1 |
The present invention relates to: oral nanoparticles for enabling oral administration of a bioactive compound which is typically administered by injection due to having low bioavailability attributable to issues with solubility, disinteg...
|
|
WO/2022/212529A1 |
A transdermal system for providing estrogen to a patient in need thereof is provided. The transdermal system comprises a backing, and a matrix contacting the backing, the matrix configured to release about 4 mcg per day to about 36 mcg p...
|
|
WO/2022/211027A1 |
The present invention provides: a CD9 signal suppressing agent that includes the amino acid sequence of RSHRLRLH (SEQ ID NO: 1) or includes the SEQ ID NO: 1 amino acid sequence where one or more amino acids are deleted, substituted, or a...
|
|
WO/2022/210514A1 |
Previously there has not been a method for producing a highly safe cell preparation which, as far as is possible, does not include components of xenogenic origin, in order to reduce cross-species rejection and the risk of transmission of...
|
|
WO/2022/210224A1 |
Provided are: a cell preparation production method with which it is possible to produce, in a simple manner, an effective cell preparation by applying an appropriate hypoxic low-sugar stimulation to peripheral blood mononuclear cells; an...
|
|
WO/2022/210536A1 |
Provided is a method for producing a composition, which contains a pharmaceutically acceptable salt of citric acid, a hydrate thereof, or a mixture thereof and has a moisture content of at most 4.0 mass%, the method comprising irradiatin...
|
